Cargando…
A systematic literature review of the human skin microbiome as biomarker for dermatological drug development
AIMS: To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne vulgaris (AV), psoriasis vulgaris (PV), hidradenitis suppurativa (HS), seborrhoeic dermatitis/pityriasis capitis (SD/PC) and ulcus cruris (UC). METHODS: A systematic lite...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138488/ https://www.ncbi.nlm.nih.gov/pubmed/29877593 http://dx.doi.org/10.1111/bcp.13662 |
_version_ | 1783355351520772096 |
---|---|
author | Niemeyer ‐ van der Kolk, T. van der Wall, H. E. C. Balmforth, C. Van Doorn, M. B. A. Rissmann, R. |
author_facet | Niemeyer ‐ van der Kolk, T. van der Wall, H. E. C. Balmforth, C. Van Doorn, M. B. A. Rissmann, R. |
author_sort | Niemeyer ‐ van der Kolk, T. |
collection | PubMed |
description | AIMS: To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne vulgaris (AV), psoriasis vulgaris (PV), hidradenitis suppurativa (HS), seborrhoeic dermatitis/pityriasis capitis (SD/PC) and ulcus cruris (UC). METHODS: A systematic literature review was conducted according to the PRISMA guidelines. Two investigators independently reviewed the included studies and ranked the suitability microbiome implementation for early phase clinical studies in an adapted GRADE method. RESULTS: In total, 841 papers were identified and after screening of titles and abstracts for eligibility we identified 42 manuscripts that could be included in the review. Eleven studies were included for AD, five for AV, 10 for PV, two for HS, four for SD and 10 for UC. For AD and AV, multiple studies report the relationship between the skin microbiome, disease severity and clinical response to treatment. This is currently lacking for the remaining conditions. CONCLUSION: For two indications – AD and AV – there is preliminary evidence to support implementation of the skin microbiome as biomarkers in early phase clinical trials. For PV, UC, SD and HS there is insufficient evidence from the literature. More microbiome‐directed prospective studies studying the effect of current treatments on the microbiome with special attention for patient meta‐data, sampling methods and analysis methods are needed to draw more substantial conclusions. |
format | Online Article Text |
id | pubmed-6138488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61384882018-09-20 A systematic literature review of the human skin microbiome as biomarker for dermatological drug development Niemeyer ‐ van der Kolk, T. van der Wall, H. E. C. Balmforth, C. Van Doorn, M. B. A. Rissmann, R. Br J Clin Pharmacol Systematic Review and Meta–Analysis AIMS: To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne vulgaris (AV), psoriasis vulgaris (PV), hidradenitis suppurativa (HS), seborrhoeic dermatitis/pityriasis capitis (SD/PC) and ulcus cruris (UC). METHODS: A systematic literature review was conducted according to the PRISMA guidelines. Two investigators independently reviewed the included studies and ranked the suitability microbiome implementation for early phase clinical studies in an adapted GRADE method. RESULTS: In total, 841 papers were identified and after screening of titles and abstracts for eligibility we identified 42 manuscripts that could be included in the review. Eleven studies were included for AD, five for AV, 10 for PV, two for HS, four for SD and 10 for UC. For AD and AV, multiple studies report the relationship between the skin microbiome, disease severity and clinical response to treatment. This is currently lacking for the remaining conditions. CONCLUSION: For two indications – AD and AV – there is preliminary evidence to support implementation of the skin microbiome as biomarkers in early phase clinical trials. For PV, UC, SD and HS there is insufficient evidence from the literature. More microbiome‐directed prospective studies studying the effect of current treatments on the microbiome with special attention for patient meta‐data, sampling methods and analysis methods are needed to draw more substantial conclusions. John Wiley and Sons Inc. 2018-07-19 2018-10 /pmc/articles/PMC6138488/ /pubmed/29877593 http://dx.doi.org/10.1111/bcp.13662 Text en © 2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Systematic Review and Meta–Analysis Niemeyer ‐ van der Kolk, T. van der Wall, H. E. C. Balmforth, C. Van Doorn, M. B. A. Rissmann, R. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title | A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title_full | A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title_fullStr | A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title_full_unstemmed | A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title_short | A systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
title_sort | systematic literature review of the human skin microbiome as biomarker for dermatological drug development |
topic | Systematic Review and Meta–Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138488/ https://www.ncbi.nlm.nih.gov/pubmed/29877593 http://dx.doi.org/10.1111/bcp.13662 |
work_keys_str_mv | AT niemeyervanderkolkt asystematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT vanderwallhec asystematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT balmforthc asystematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT vandoornmba asystematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT rissmannr asystematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT niemeyervanderkolkt systematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT vanderwallhec systematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT balmforthc systematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT vandoornmba systematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment AT rissmannr systematicliteraturereviewofthehumanskinmicrobiomeasbiomarkerfordermatologicaldrugdevelopment |